Drug Profile
GT 389255
Alternative Names: GT389-255Latest Information Update: 31 Mar 2022
Price :
$50
*
At a glance
- Originator Genzyme Corporation
- Developer Peptimmune
- Class Obesity therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 31 Oct 2005 Phase-II clinical trials in Obesity in USA (unspecified route)
- 17 May 2005 Peptimmune has completed a phase Ib trial in obesity in USA
- 11 Aug 2004 Phase-I clinical trials in Obesity in USA (unspecified route)